Multivalent recombinant OspA Lyme Borreliosis Vaccine
730901
Phase 2 mab completed
Quick answer
Multivalent recombinant OspA Lyme Borreliosis Vaccine for Prophylaxis of Lyme Borreliosis is a Phase 2 program (mab) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Prophylaxis of Lyme Borreliosis
- Phase
- Phase 2
- Modality
- mab
- Status
- completed